What long-acting insulin will Medicare cover?

Medicare covers long-acting insulin, and your out-of-pocket cost is capped at a maximum of $35 per month for each prescription.

How Medicare Covers Long-Acting Insulin

• Medicare Part D (Prescription Drug Plans): Covers standard long-acting injectable insulin pens or vials (such as Lantus, Basaglar, or Levemir) that you inject yourself. The yearly deductible is waived for insulin.
• Medicare Part B (Medical Insurance): Covers long-acting insulin only if it is delivered through a traditional, medically necessary external insulin pump approved as durable medical equipment.
• Cost Cap: Under the Centers for Medicare & Medicaid Services guidelines from the Inflation Reduction Act, you pay no more than $35 for a one-month supply of each covered long-acting insulin product, and up to $105 for a three-month supply.

What Else is Covered

• Part D Supplies: If you get your insulin via Part D, the plan also covers related administration supplies like syringes and needles.
• Part B Supplies: If you use a Part B pump, the pump and its specific operating supplies are covered under Part B rules (subject to 20% coinsurance after the deductible), but the insulin itself remains capped at $35.

Under federal law, Lantus costs a maximum of $35 per one-month supply for anyone enrolled in Medicare Part D (prescription drug plans) or Medicare Part B.

The $35 monthly price cap means your out-of-pocket costs are strictly limited:

• No Deductible: You do not have to meet your annual Medicare drug deductible before this pricing kicks in. The $35 cap applies from your very first fill of the year.
• Three-Month Supplies: If your doctor prescribes a 3-month supply, your cost is capped at $105.
• Per-Product Rule: The $35 cap applies per covered insulin product. If you use Lantus alongside a rapid-acting insulin (like Humalog), you will pay up to $35 for Lantus and up to $35 for the other insulin.
• Income Subsidies: If you qualify for Medicare’s Extra Help program, your monthly cost for Lantus could be even lower, ranging from $0 to a few dollars.

⚠️ Critical Plan Requirements & Limits

While the law sets a hard limit, you must verify how your specific coverage handles Lantus:

• The Formulary Check: The $35 cap only applies if Lantus is on your specific Medicare plan's formulary (list of covered drugs). Because lower-cost, interchangeable biosimilars like Rezvoglar and Semglee are widely available, some Medicare plans prefer the biosimilars and may exclude the brand-name Lantus. If your plan excludes Lantus, you could be charged full retail price.
• Part B vs. Part D Delivery: If you inject Lantus via a standard syringe or prefilled SoloStar pen, it is covered under Part D. If you use a traditional durable medical equipment (DME) pump, it falls under Part B. Both parts honor the $35 cap, but supply coverage rules differ.

💡 Alternative Savings If Lantus Isn't Covered

If you look up your plan via the Medicare Plan Finder and discover Lantus is excluded from the formulary, you can still secure the $35 price tag:

1. Manufacturer Program: Sanofi offers the Sanofi Insulins Valyou Savings Program, which allows patients to pay cash outside of insurance and still get Lantus for $35 per month.
2. Pharmacy Coupons: Platforms like GoodRx feature direct cash-pay coupon partnerships with Sanofi to match the $35 price at retail pharmacies.

In 2026, you can compare plans or view details on the Medicare Part D Plans for Insulin page, where your out-of-pocket cost for each covered insulin product is capped at no more than $35 for a one-month supply, with the yearly deductible waived.

Key Details for 2026 Insulin Coverage

• Monthly Cost Cap: You pay a maximum of $35 per month (or less if 25% of the negotiated price or Maximum Fair Price is lower) for each covered insulin product under Medicare Part D and Part B.
• Deductible Waived: The prescription drug deductible does not apply to covered insulin products.
• Part B vs. Part D: Part B covers traditional pump-delivered insulin (where you may pay 20% of the approved amount after meeting the Part B deductible, unless a specific Part D rule applies), while Part D covers injectable, inhaled, and non-pump insulins with the $35 cap.
• General Out-of-Pocket Limit: The total annual out-of-pocket cap for covered Part D prescription drugs reaches $2,100 in 2026, after which you pay $0 for covered drugs for the rest of the year.

Yes, insulin is still capped at no more than $35 per month for a one-month supply of each covered insulin product for Medicare patients.

Key Details on the $35 Insulin Cap

• Medicare Part D: Covers retail injectable and inhaled insulin, capping costs at $35 per month per product with no deductible.
• Medicare Part B: Covers insulin used through a traditional traditional durable medical equipment (DME) infusion pump, also capped at $35 per month with no deductible.
• No Deductibles: You do not have to pay a yearly deductible before the $35 cap kicks in for covered insulin.
• Multiple Months: If you order a three-month supply, you will pay no more than $105 total per covered product ($35 per month).
• Official Information: You can review official updates and covered products directly on the Medicare Insulin Coverage Page.

Under Medicare, Tresiba will cost you a maximum of $35 for a 30-day supply.

Thanks to the federal Inflation Reduction Act, all covered insulins are capped at a $35 monthly copay for Medicare beneficiaries. This price ceiling applies even if you haven't met your annual prescription deductible yet.

Breakdown of Medicare Costs for Tresiba

• Standard Medicare Part D / Medicare Advantage Copay: Maximum $35 per 30-day supply. Some plans may choose to charge less.
• Low-Income Subsidy (Extra Help) Enrollees: $11.20 or less per month.
• Annual Medication Out-of-Pocket Cap: $2,100. For covered drugs under your Medicare plan, you will never pay more than this cumulative cap in a calendar year. Once you hit it, your plan covers 100% of your medication costs.

Crucial Coverage Checks

While the price is capped, Tresiba must be included on your specific Medicare plan's formulary (list of covered drugs) for the $35 cap to apply. Tresiba is covered by a high percentage of Medicare Part D plans nationwide, but some providers require "step therapy" (forcing you to try cheaper long-acting alternatives like Lantus first).

Always check your plan's formulary through the Medicare Plan Finder or contact your insurance company directly to verify that Tresiba is actively covered.

What if my Medicare plan doesn't cover Tresiba?

If your plan excludes Tresiba, you will initially be charged the retail cash price, which can exceed $400 to $700 depending on whether you use vials or FlexTouch pens. If you face this situation, you have a few options:

1. Patient Assistance Programs: Novo Nordisk offers a Patient Assistance Program (PAP) that provides free Tresiba to qualifying low-income individuals, which explicitly includes Medicare enrollees who meet certain financial criteria.
2. Pharmacy Discount Cards: Coupon providers like SingleCare or GoodRx can bring the out-of-pocket cash price down to roughly $94 to $123. However, these coupons cannot be combined with Medicare benefits.
3. Manufacturer Copay Cards Note: You may see Novo Nordisk advertising a copay card for $35 to $99; Medicare beneficiaries are legally prohibited from using these manufacturer coupons due to federal anti-kickback laws.